Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Review

Long non-coding RNAs: emerging players in osteosarcoma

Authors: Zheng Li, Xin Yu, Jianxiong Shen

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

Osteosarcoma is the most common kind of primary bone tumors with high morbidity in infants and adolescents. While the molecular mechanism of osteosarcoma has gained considerable attention, the mechanisms underlying its initiation and progression remain unclear. Recent studies have discovered that long non-coding RNAs (lncRNAs) play an important role in multiply biological processes including cell development, differentiation, proliferation, invasion, and migration. Deregulated expression of lncRNAs has been found in cancers including osteosarcoma. This review summarized the deregulation and functional role of lncRNAs in osteosarcoma and their potential application for diagnosis and treatment of osteosarcoma.
Literature
1.
Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH, Wang WJ. Micrornas in osteosarcoma. Clin Chim Acta. 2015;444:9–17.CrossRefPubMed
2.
Weng Y, Chen Y, Chen J, Liu Y, Bao T. Common genetic variants in microrna processing machinery genes are associated with risk and survival in patients with osteosarcoma. Mol Gen Genomics. 2015. [Epub ahead of print].
3.
Wang Y, Jia LS, Yuan W, Wu Z, Wang HB, Xu T, et al. Low mir-34a and mir-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma. Am J Trans Res. 2015;7:111–9.
4.
Shen L, Chen XD, Zhang YH. Microrna-128 promotes proliferation in osteosarcoma cells by downregulating pten. Tumour Biol. 2014;35:2069–74.CrossRefPubMed
5.
Huang J, Gao K, Lin J, Wang Q. Microrna-100 inhibits osteosarcoma cell proliferation by targeting cyr61. Tumour Biol. 2014;35:1095–100.CrossRefPubMed
6.
Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif. 2014;47:427–34.CrossRefPubMed
7.
Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM, et al. Mir-16 inhibits cell proliferation by targeting igf1r and the raf1-mek1/2-erk1/2 pathway in osteosarcoma. FEBS Lett. 2013;587:1366–72.CrossRefPubMed
8.
Han K, Chen X, Bian N, Ma B, Yang T, Cai C, et al. Microrna profiling identifies mir-195 suppresses osteosarcoma cell metastasis by targeting ccnd1. Oncotarget. 2015.
9.
Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, et al. Mir-27a and mir-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget. 2015;6:4920–35.CrossRefPubMedPubMedCentral
10.
Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ, Tang CH. Ctgf increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating mir-519d. Oncotarget. 2014;5:3800–12.CrossRefPubMedPubMedCentral
11.
Cheng C, Chen ZQ, Shi XT. Microrna-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol. 2014;35:4177–83.CrossRefPubMed
12.
Li E, Zhang J, Yuan T, Ma B. Mir-145 inhibits osteosarcoma cells proliferation and invasion by targeting rock1. Tumour Biol. 2014;35:7645–50.CrossRefPubMed
13.
14.
Li CH, Chen Y. Targeting long non-coding rnas in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45:1895–910.CrossRefPubMed
15.
Chiyomaru T, Fukuhara S, Saini S, Majid S, Deng G, Shahryari V, et al. Long non-coding rna hotair is targeted and regulated by mir-141 in human cancer cells. J Biol Chem. 2014;289:12550–65.CrossRefPubMedPubMedCentral
16.
Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding rnas: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.CrossRefPubMed
17.
Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, et al. Long non-coding rna anril (cdkn2b-as) is induced by the atm-e2f1 signaling pathway. Cell Signal. 2013;25:1086–95.CrossRefPubMedPubMedCentral
18.
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, et al. Long noncoding rna associated-competing endogenous rnas in gastric cancer. Sci Rep. 2014;4:6088.PubMedPubMedCentral
19.
Yu X, Li Z. Long non-coding rna hotair: a novel oncogene (review). Mol Med Rep. 2015;12:5611–8.PubMed
20.
21.
Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W, et al. Long non-coding rna ccat1 promotes gallbladder cancer development via negative modulation of mirna-218-5p. Cell Death Dis. 2015;6, e1583.CrossRefPubMedPubMedCentral
22.
Zhou S, Wang J, Zhang Z. An emerging understanding of long noncoding rnas in kidney cancer. J Cancer Res Clin Oncol. 2014.
23.
Nie FQ, Sun M, Yang JS, Xie M, Xu TP, Xia R, et al. Long noncoding rna anril promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing klf2 and p21 expression. Mol Cancer Ther. 2015;14:268–77.CrossRefPubMed
24.
Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long noncoding rna anril indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of mir-99a/mir-449a. Oncotarget. 2014;5:2276–92.CrossRefPubMedPubMedCentral
25.
Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, et al. Expression analysis of four long noncoding rnas in breast cancer. Tumour Biol. 2015.
26.
Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ, Ma WL. High expression of long non-coding rna anril is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8:3076–82.PubMedPubMedCentral
27.
Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, Hua KQ. Long non-coding rna anril predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol. 2015;46:2497–505.PubMed
28.
Martinez-Fernandez M, Feber A, Duenas M, Segovia C, Rubio C, Fernandez M, et al. Analysis of the polycomb-related lncrnas hotair and anril in bladder cancer. Clin Epigenetics. 2015;7:109.CrossRefPubMedPubMedCentral
29.
Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, et al. Decreased expression of long noncoding rna gas5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer. 2014;14:319.CrossRefPubMedPubMedCentral
30.
Li JP, Liu LH, Li J, Chen Y, Jiang XW, Ouyang YR, et al. Microarray expression profile of long noncoding rnas in human osteosarcoma. Biochem Biophys Res Commun. 2013;433:200–6.CrossRefPubMed
31.
Zhu KP, Zhang CL, Shen GQ, Zhu ZS. Long noncoding rna expression profiles of the doxorubicin-resistant human osteosarcoma cell line mg63/dxr and its parental cell line mg63 as ascertained by microarray analysis. Int J Clin Exp Pathol. 2015;8:8754–73.PubMedPubMedCentral
32.
Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S. Malat1 long non-coding rna in cancer. Biochim Biophys Acta. 2015.
33.
Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng J, et al. Lncrna malat1 functions as a competing endogenous rna to regulate zeb2 expression by sponging mir-200s in clear cell kidney carcinoma. Oncotarget. 2015;6:38005–15.PubMedPubMedCentral
34.
Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, et al. Lncrna malat1 enhances oncogenic activities of ezh2 in castration-resistant prostate cancer. Oncotarget. 2015.
35.
Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding malat-1 rna indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984–92.CrossRefPubMed
36.
Zhou X, Liu S, Cai G, Kong L, Zhang T, Ren Y, et al. Long non coding rna malat1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci Rep. 2015;5:15972.CrossRefPubMedPubMedCentral
37.
Jin C, Yan B, Lu Q, Lin Y, Ma L. The role of malat1/mir-1/slug axis on radioresistance in nasopharyngeal carcinoma. Tumour Biol. 2015.
38.
Huang Z, Huang L, Shen S, Li J, Lu H, Mo W, et al. Sp1 cooperates with sp3 to upregulate malat1 expression in human hepatocellular carcinoma. Oncol Rep. 2015;34:2403–12.PubMed
39.
Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, et al. Low expression of loc285194 is associated with poor prognosis in colorectal cancer. J Transl Med. 2013;11:122.CrossRefPubMedPubMedCentral
40.
Ding YC, Yu W, Ma C, Wang Q, Huang CS, Huang T. Expression of long non-coding rna loc285194 and its prognostic significance in human pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2014;7:8065–70.PubMedPubMedCentral
41.
Lu H, He Y, Lin L, Qi Z, Ma L, Li L, et al. Long non-coding rna malat1 modulates radiosensitivity of hr-hpv+ cervical cancer via sponging mir-145. Tumour Biol. 2015.
42.
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Tgf-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 2014;20:1531–41.CrossRefPubMed
43.
Xu S, Sui S, Zhang J, Bai N, Shi Q, Zhang G, et al. Downregulation of long noncoding rna malat1 induces epithelial-to-mesenchymal transition via the pi3k-akt pathway in breast cancer. Int J Clin Exp Pathol. 2015;8:4881–91.PubMedPubMedCentral
44.
45.
Konishi H, Ichikawa D, Yamamoto Y, Arita T, Shoda K, Hiramoto H, et al. Plasma malat1 level is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci. 2015.
46.
Taniguchi M, Fujiwara K, Nakai Y, Ozaki T, Koshikawa N, Toshio K, et al. Inhibition of malignant phenotypes of human osteosarcoma cells by a gene silencer, a pyrrole-imidazole polyamide, which targets an e-box motif. FEBS Open Bio. 2014;4:328–34.CrossRefPubMedPubMedCentral
47.
Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. Malat1 promotes the proliferation and metastasis of osteosarcoma cells by activating the pi3k/akt pathway. Tumour Biol. 2015;36:1477–86.CrossRefPubMed
48.
Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, et al. 17beta-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating mir-9 and thus degrades malat-1 in osteosarcoma cell mg-63 in an estrogen receptor-independent manner. Biochem Biophys Res Commun. 2015;457:500–6.CrossRefPubMed
49.
Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S, et al. Long noncoding rna malat1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2015.
50.
Young TL, Matsuda T, Cepko CL. The noncoding rna taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol. 2005;15:501–12.CrossRefPubMed
51.
Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, et al. P53-regulated long non-coding rna tug1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating hoxb7 expression. Cell Death Dis. 2014;5, e1243.CrossRefPubMedPubMedCentral
52.
Han Y, Liu Y, Gui Y, Cai Z. Long intergenic non-coding rna tug1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol. 2013;107:555–9.CrossRefPubMed
53.
Huang MD, Chen WM, Qi FZ, Sun M, Xu TP, Ma P, et al. Long non-coding rna tug1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of klf2. Mol Cancer. 2015;14:165.CrossRefPubMedPubMedCentral
54.
Xu Y, Wang J, Qiu M, Xu L, Li M, Jiang F, et al. Upregulation of the long noncoding rna tug1 promotes proliferation and migration of esophageal squamous cell carcinoma. Tumour Biol. 2015;36:1643–51.CrossRefPubMed
55.
Zhang Q, Geng PL, Yin P, Wang XL, Jia JP, Yao J. Down-regulation of long non-coding rna tug1 inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J Cancer Prev. 2013;14:2311–5.CrossRefPubMed
56.
Ma B, Li M, Zhang L, Huang M, Lei JB, Fu GH, et al. Upregulation of long non-coding rna tug1 correlates with poor prognosis and disease status in osteosarcoma. Tumour Biol. 2015.
57.
Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X, et al. A novel long non-coding rna, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. Mol Med Rep. 2015;11:2534–40.PubMed
58.
Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, et al. Long non-coding rna h19 promotes glioma cell invasion by deriving mir-675. PLoS One. 2014;9, e86295.CrossRefPubMedPubMedCentral
59.
Jiang X, Yan Y, Hu M, Chen X, Wang Y, Dai Y. Increased level of h19 long noncoding rna promotes invasion, angiogenesis, and stemness of glioblastoma cells. J Neurosurg. 2015:1-8. [Epub ahead of print].
60.
Raveh E, Matouk IJ, Gilon M, Hochberg A. The h19 long non-coding rna in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer. 2015;14:184.CrossRefPubMedPubMedCentral
61.
Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19-derived mir-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 2015.
62.
Zhang E, Li W, Yin D, De W, Sun S, Han L. C-myc-regulated long non-coding rna h19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol. 2015.
63.
Li H, Li J, Jia S, Wu M, An J, Zheng Q, et al. Mir675 upregulates long noncoding rna h19 through activating egr1 in human liver cancer. Oncotarget. 2015;6:31958–84.PubMedPubMedCentral
64.
Zhou X, Ye F, Yin C, Zhuang Y, Yue G, Zhang G. The interaction between mir-141 and lncrna-h19 in regulating cell proliferation and migration in gastric cancer. Cell Physiol Biochem. 2015;36:1440–52.CrossRefPubMed
65.
Zhu Z, Song L, He J, Sun Y, Liu X, Zou X. Ectopic expressed long non-coding rna h19 contributes to malignant cell behavior of ovarian cancer. Int J Clin Exp Pathol. 2015;8:10082–91.PubMedPubMedCentral
66.
Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, et al. Loss of imprinting of igf2 and h19 in osteosarcoma is accompanied by reciprocal methylation changes of a ctcf-binding site. Hum Mol Genet. 2003;12:535–49.CrossRefPubMed
67.
Ulaner GA, Yang Y, Hu JF, Li T, Vu TH, Hoffman AR. Ctcf binding at the insulin-like growth factor-ii (igf2)/h19 imprinting control region is insufficient to regulate igf2/h19 expression in human tissues. Endocrinology. 2003;144:4420–6.CrossRefPubMed
68.
Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol. 2008;84:234–9.CrossRefPubMed
69.
Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through yap1 and h19 overexpression. Oncogene. 2014;33:4857–66.CrossRefPubMed
70.
Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding rnas and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res. 2010;70:160–71.CrossRefPubMed
71.
Metadata
Title
Long non-coding RNAs: emerging players in osteosarcoma
Authors
Zheng Li
Xin Yu
Jianxiong Shen
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4749-4

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization

Original Article

XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma

Original Article

The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas

Original Article

Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo

Original Article

Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer

Original Article

ROCK inhibitor Y-27632 inhibits the growth, migration, and invasion of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits